ECA39 is a novel distant metastasis-related biomarker in colorectal cancer

Abstract

Aim: To investigate the possible role of polysaccharide-K (PSK) -related markers in predicting distant metastasis and in the clinical outcome of colorectal cancer (CRC).

Methods: Firstly, we used protein microarrays to analyze the in vitro expression profiles of potential PSK-related markers in the human colorectal adenocarcinoma cell line SW480, which carries a mutant p53 gene. Then, we investigated the clinical implications of these markers in the prognosis of CRC patients.

Results: ECA39, a direct target of c-Myc, was identified as a candidate protein affected by the anti-metastatic effects of PSK. Immunohistochemistry revealed that ECA39 was expressed at significantly higher levels in tumor tissues with distant metastases compared to those without (P<0.00001). Positive ECA39 expression was shown to be highly reliable for the prediction of distant metastases (sensitivity: 86.7%, specificity: 90%, positive predictive value: 86.7%, negative predictive value: 90%). A significantly higher cumulative 5-yr disease free survival rate was observed in the ECA39-negative patient group (77.3%) compared with the ECA39-positive patient group (25.8%) (P<0.05).

Conclusion: Our results suggest that ECA39 is a dominant predictive factor for distant metastasis in patients with advanced CRC and that its suppression by PSK might represent a useful application of immunotherapy as part of a program of integrated medicine.

Figure 1

Immunohistochemical detection of ECA39 in rectal cancers (A: × 40; B: × 100. Bars indicate 100 μm).

Figure 2

Five-year disease-free survival curves for eligible patients with pathologic stage III cancer in the ECA39-negative group and ECA39-positive group.

Figure 3

Five-year overall survival curves for eligible patients with pathologic stage III cancer in the ECA39-negative group and ECA39-positive group.